Pay in 4 interest-free payments of $7.50 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Acta Crystallogr C
Treatment with 5 μM ROC-325 for 24 hours leads to the formation of LC3B punctae and a robust increase in LC3B levels in both A498 and 786-0 RCC cells
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
or 50 μM) has no effect on cell viability
Formula: C28H29ClN4O3
LY2835219 free base - CAS# 1231929-97-7 size:2mg solid Acta Crystallogr CLY2835219 free base, CAS No. 1231929 97 7, is orally available cyclin dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK mediated
US$ 28.00
US$ 28.00
US$ 29.00
US$ 26.00
US$ 20.00
US$ 41.00
US$ 23.95
US$ 24.95